LASIX
LOE ApproachingNDAORALSOLUTION
Approved
Mar 1977
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
4/8 — Partial
LASIX by Sanofi is 12. Approved for edema in adult patients with chronic heart failure. First approved in 1977.
Drug data last refreshed 5h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LASIX (furosemide) is a loop diuretic that inhibits sodium and chloride reabsorption in the proximal and distal tubules and loop of Henle, producing significant diuresis. It is indicated for edema in adult patients with chronic heart failure (NYHA Class II–III). The drug has been reformulated as Lasix ONYU for subcutaneous infusion, offering an alternative to intravenous administration with comparable efficacy and 8+ hours of diuretic effect.
LOE Approaching
Product is approaching loss of exclusivity with minimal ongoing investment; commercial teams are likely in maintenance mode with reduced headcount.
Mechanism of Action
12.1 Mechanism of Action Furosemide primarily inhibits the reabsorption of sodium and chloride in the proximal and distal tubules and in the loop of Henle. The high degree of diuresis is largely due to the unique site of action. The action on the distal tubule is independent of any inhibitory…
Worked on LASIX at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.